Breakthrough Bispecific Inhibitor Targets Multiple Coronaviruses, Including Resistant Strains
A groundbreaking bispecific inhibitor has been developed to combat a wide range of coronaviruses, including Paxlovid-resistant variants, offering hope for more resilient antiviral therapies.
Researchers from the University of Hong Kong and Sichuan University have developed an innovative bispecific inhibitor, named TMP1, capable of fighting a broad spectrum of human-infecting coronaviruses. Significantly, this novel compound can target viruses resistant to current treatments like Paxlovid, offering a promising new avenue for antiviral therapy. The inhibitor works by simultaneously targeting two crucial viral and host factors: the viral main protease (Mpro) and the host enzyme TMPRSS2, which facilitates viral entry into human cells. Using advanced chemical synthesis techniques, scientists optimized small molecules to create TMP1, demonstrating its stability in vivo and potent antiviral efficacy against major coronaviruses, including SARS-CoV-2, SARS-CoV-1, and MERS-CoV. Notably, TMP1 was effective in protecting hamsters from SARS-CoV-2 transmission and showed resilience against drug-resistant viral mutants. This bispecific approach marks a significant advancement, potentially overcoming limitations of current mono-target drugs and reducing the chances of resistance development. The study, published in Nature Communications, underscores the potential for next-generation antivirals that provide more comprehensive protection against existing and emerging coronaviruses.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
'Rhythm beats volume': How the brain preserves our perception of familiarity
New research reveals that neuronal rhythms, rather than firing rates, play a key role in how the brain maintains a stable perception of the world, providing insights for future brain-computer technologies and therapies.
Low-Dose Old Drug Shows Promise in Preventing Type 1 Diabetes Progression in Youths
A groundbreaking study shows that a low dose of the old immunomodulatory drug ATG is safe and effective in slowing the progression of type 1 diabetes in children and young adults, opening new avenues for disease modification.
FDA Recalls Chocolate Candies Due to Milk Allergy Concerns
The FDA has issued a voluntary recall of certain chocolate candies due to undeclared milk, posing serious allergy risks. Consumers should check lot numbers to avoid potential health hazards.